Photography is a key business tool for fashion portraits beauty shots or commercial images While enhancing the subject natural skin texture is important it equally crucial to maintain authenticity and ...

The phase II NEO trial data, featured on January 25, 2025, shows that the liquid biopsy tool can aid in decision-making for organ preservation in patients with node-negative rectal cancer undergoing ...

Clinical-stage Australian biotechnology company Immutep (ASX:IMM) has completed enrolment in the investigator-initiated EFTISARC-NEO trial. EFTISARC-NEO is evaluating Immutep's investigative LAG-3 ...

The phase II NEO trial data, featured on January 25, 2025, shows that the liquid biopsy tool can aid in decision-making for organ preservation in patients with node-negative rectal cancer ...

Phase II trial evaluating efti in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) in patients with soft tissue sarcoma reaches enrolment target of 40 patients Data updates from ...

The trial is designed to evaluate eftilagimod alpha or efti in combination with radiotherapy and KEYTRUDA or pembrolizumab in patients with resectable soft tissue sarcoma or STS. EFTISARC-NEO is ...

Data updates from EFTISARC-NEO are expected in 2025. For more information on the trial, please visit clinicaltrials.gov (NCT06128863). Immutep is a clinical-stage biotechnology company developing ...

22, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and ...